Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance

Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance

The predictive factors of long-term clinical benefits in patients with hepatitis C virus (HCV)—related liver cirrhosis after Direct Antiviral Agents (DAA) treatment are still undefined. The aim of this study was to identify any predictors of liver failure, hepatocellular carcinoma (HCC) and/or death...

Full description

Bibliographic Details
Main Authors: Maria Stella Franzè, Roberto Filomia, Gaia Caccamo, Concetta Pitrone, Angela Alibrandi, Carlo Saitta, Amalia Rita Caspanello, Clelia Asero, Vittoria Arcadi, Giovanni Raimondo, Irene Cacciola
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Journal of Personalized Medicine
Subjects:
hypergammaglobulinemia
DAA treatment
liver cirrhosis
HCV clearance
hepatocellular carcinoma
liver decompensation
Online Access:https://www.mdpi.com/2075-4426/12/11/1794

Similar Items

Similar Items